title: Longitudinal study of new eye lesions in treated congenital toxoplasmosis.
abstract: OBJECTIVE
  To determine the incidence of new chorioretinal lesions in patients with congenital toxoplasmosis who were treated throughout their first year of life.
  
  
  METHODS
  Prospective longitudinal observation of a cohort.
  
  
  METHODS
  One hundred thirty-two children were studied as part of the longitudinal observation.
  
  
  METHODS
  One hundred thirty-two children were treated during their first year of life with pyrimethamine, sulfadiazine, and leucovorin. They had eye examinations at prespecified intervals.
  
  
  METHODS
  New chorioretinal lesions on fundus examination and fundus photographs.
  
  
  RESULTS
  The mean age (+/- standard deviation) is 10.8+/-5.1 years (range, 0.2-23). One hundred eight children have been evaluated for new chorioretinal lesions. Thirty-four (31%; 95% confidence interval, 23%-41%) of 108 children developed at least one chorioretinal lesion that was previously undetected. These occurred at varying times during their follow-up course. Fifteen children (14%) developed new central lesions, and 27 (25%) had newly detected lesions peripherally. Ten (9%) had more than one occurrence of new lesions developing, and 13 (12%) had new lesions in both eyes. Of those who developed new lesions, 14 children (41%) did so at age 10 or later.
  
  
  CONCLUSIONS
  New central chorioretinal lesions are uncommon in children with congenital toxoplasmosis who are treated during their first year of life. This finding contrasts markedly with earlier reports in the literature for untreated children or those treated for only 1 month near birth, in whom new lesions were much more prevalent (>/=82%). Our observation that 14 (41%) of the 34 children with new chorioretinal lesions had occurrences when they were 10 years or older indicates that long-term follow-up into the second decade of life is important in assessing the efficacy of treating toxoplasmosis during infancy.
authors.affiliation: University of Chicago School of Medicine, Chicago, Illinois 60637, USA.
authors.forename: Laura
authors.initials: L
authors.lastname: Phan
authors.forename: Kristen
authors.initials: K
authors.lastname: Kasza
authors.forename: Jessica
authors.initials: J
authors.lastname: Jalbrzikowski
authors.forename: A Gwendolyn
authors.initials: AG
authors.lastname: Noble
authors.forename: Paul
authors.initials: P
authors.lastname: Latkany
authors.forename: Annie
authors.initials: A
authors.lastname: Kuo
authors.forename: William
authors.initials: W
authors.lastname: Mieler
authors.forename: Sanford
authors.initials: S
authors.lastname: Meyers
authors.forename: Peter
authors.initials: P
authors.lastname: Rabiah
authors.forename: Ken
authors.initials: K
authors.lastname: Boyer
authors.forename: Charles
authors.initials: C
authors.lastname: Swisher
authors.forename: Marilyn
authors.initials: M
authors.lastname: Mets
authors.forename: Nancy
authors.initials: N
authors.lastname: Roizen
authors.forename: Simone
authors.initials: S
authors.lastname: Cezar
authors.forename: Jack
authors.initials: J
authors.lastname: Remington
authors.forename: Paul
authors.initials: P
authors.lastname: Meier
authors.forename: Rima
authors.initials: R
authors.lastname: McLeod
mesh_terms: D000293:Adolescent; D000328:Adult; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D002955:Leucovorin / Q000627:therapeutic use; D008137:Longitudinal Studies; D008297:Male; D011446:Prospective Studies; D011739:Pyrimethamine / Q000627:therapeutic use; D012008:Recurrence; D012164:Retinal Diseases / Q000175:diagnosis* / Q000188:drug therapy; D013411:Sulfadiazine / Q000627:therapeutic use; D014125:Toxoplasmosis, Congenital / Q000175:diagnosis* / Q000188:drug therapy; D014126:Toxoplasmosis, Ocular / Q000175:diagnosis* / Q000188:drug therapy